Stock exchanges & markets

Overview Watchlists

FDA approves Novartis Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer

31. Jul 2026

(AWP Alliance News) - Novartis secured FDA clearance for Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer. The decision expands Pluvicto use across PSMA-positive metastatic disease, nearly doubling the eligible patient pool.

In the Phase III PSMAddition trial, the regimen cut the risk of progression or death by 33% at an updated analysis, with an overall survival trend favoring treatment (HR 0.80).

https://www.publicnow.com/view/A0A5E18C3E1DC84B69FAF98C375DB127E4752F5D…

Disclaimer: This news brief was created using generative artificial intelligence. Novartis AG published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • ETF Compass

    Stock exchanges & markets

    ETFs are becoming increasingly popular. Our ETF Compass helps you maintain an overview. Filter by criteria such as asset class, region, rating, return or costs. 

    Try the ETF Compass now

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now